StockData

IRulya Therapeutics Inc. (IRLA) stock

IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$38.45+1.09 (+2.92%)

Close on Nov 17, 2026Market cap $39.11MP/E –Yield –

IRulya Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

IRulya Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$46.92M. For fiscal 2025 it was -$41.43M. The highest annual figure on record is -$11.70M in fiscal 2018.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$41.43M–
FY2024Dec 31, 2024-$31.90M–
FY2023Dec 31, 2023-$18.29M–
FY2022Dec 31, 2022-$44.04M–
FY2021Dec 31, 2021-$62.93M–
FY2020Dec 31, 2020-$50.82M–
FY2019Dec 31, 2019-$33.28M–
FY2018Dec 31, 2018-$11.70M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$18.89M–
Q1 FY2026Mar 31, 2026-$7.63M–
Q4 FY2025Dec 31, 2025-$10.48M–
Q3 FY2025Sep 30, 2025-$9.93M–
Q2 FY2025Jun 30, 2025-$11.42M–
Q1 FY2025Mar 31, 2025-$9.60M–
Q4 FY2024Dec 31, 2024-$7.55M–
Q3 FY2024Sep 30, 2024-$7.26M–
Q2 FY2024Jun 30, 2024-$8.74M–
Q1 FY2024Mar 31, 2024-$8.35M–
Q4 FY2023Dec 31, 2023-$6.08M–
Q3 FY2023Sep 30, 2023-$4.82M–
Q2 FY2023Jun 30, 2023-$3.83M–
Q1 FY2023Mar 31, 2023-$3.57M–
Q4 FY2022Dec 31, 2022-$5.84M–
Q3 FY2022Sep 30, 2022-$6.70M–
Q2 FY2022Jun 30, 2022-$15.42M–
Q1 FY2022Mar 31, 2022-$16.09M–
Q4 FY2021Dec 31, 2021-$14.42M–
Q3 FY2021Sep 30, 2021-$17.34M–
Q2 FY2021Jun 30, 2021-$17.56M–
Q1 FY2021Mar 31, 2021-$13.61M–
Q4 FY2020Dec 31, 2020-$13.28M–
Q3 FY2020Sep 30, 2020-$12.37M–
Q2 FY2020Jun 30, 2020-$14.39M–
Q1 FY2020Mar 31, 2020-$10.78M–
Q4 FY2019Dec 31, 2019-$10.95M–
Q3 FY2019Sep 30, 2019-$8.80M–
Q2 FY2019Jun 30, 2019-$6.32M–
Q1 FY2019Mar 31, 2019-$7.22M–
Q4 FY2018Dec 31, 2018-$3.97M–
Q3 FY2018Sep 30, 2018-$1.93M–
Q2 FY2018Jun 30, 2018-$2.62M–
Q1 FY2018Mar 31, 2018-$3.18M–

More IRulya Therapeutics figures

See a number that looks wrong?